Key facts
- Lannacheng Biotech’s last known valuation is $406.0M (Feb 2025).
- It has raised $132.1M; the latest was IPO in Sep 2025.
- Notable investors include Shenzhen Capital Group, Qianhai FoF, Yeda Economic Development Group, Inner Mongolia New Energy Investment Funds Management, China Cinda Asset Management — 12 tracked in total.
- Status: In IPO Registration.
Investors
12+- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Lannacheng Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Lannacheng Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lannacheng Biotech
Developer of oncological nuclear medicine platform designed for cancer treatment. The company focuses on building a global platform for innovative nuclear medicine for the diagnosis and treatment of various types of cancer, providing the healthcare and oncology sectors with comprehensive, innovative solutions for cancer care.
- Sector
- Healthcare
- HQ
- Yantai, China
- Founded
- 2021
- Website
- dc-lnc.com/
- Ownership
- In IPO Registration
Lannacheng Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lannacheng Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lannacheng Biotech in its N-PORT filings yet. We sweep new filings monthly.